# Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

> **NCT00814073** · PHASE3 · COMPLETED · sponsor: **AB Science** · enrollment: 135 (actual)

## Conditions studied

- Indolent Systemic Mastocytosis

## Interventions

- **DRUG:** Masitinib
- **DRUG:** Placebo
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT00814073
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814073, "Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00814073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*